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ABSTRACT
Skin cancer is the most common type of malignancy affecting both men and women in the
United States. A majority of these cases are nonmelanoma skin cancers (NMSC) such as basal cell
carcinoma (BCC) and squamous cell carcinoma (SCC). The goal of any skin cancer treatment is
to cure the lesion itself while also preserving function and optimizing superficial cosmesis. High
dose rate (HDR) brachytherapy provides an alternative to superficial x-ray or electron beam for
skin cancer treatment. Utilizing an Iridium 192 source soldered to the end of a wire, surface dose
can be administered at predetermined positions with sharper dose fall off than x-ray or electron
beams. A variety of applicators are available to guide the HDR source wire to the specified
location. The Harrison Anderson Mick (H.A.M.) applicator is an HDR surface applicator designed
to create defined spacing between the source, tissue, and source channels. The pliable nature of
the flap allows for customizable contouring to the patient’s treatment area. This project is designed
around the general implementation and commissioning of a H.A.M applicator flap for HDR skin
cancer brachytherapy and the acceptance and commissioning of a Varian Bravos HDR afterloader.
Dimensional analysis of the applicators matched manufacturer specifications and each applicator
was free from damage. Applicator dosimetry was verified using Gafchromic EBT3 film and
RIT113 film analysis software. Prescription depth and dose recommendations are presented and
both treatment planning and quality assurance methods were established. End-to-end testing
performed using the applicators demonstrated that they are adequate and capable of HDR
treatment.
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1) INTRODUCTION
Nonmelanoma skin cancer (NMSC) is the most prevalent malignancy affecting both men
and women in the United States. It is estimated that at least 2-3 million people are affected
annually (Guinot et al., 2018; Ouhib et al., 2015). Basal cell carcinoma (BCC) and squamous cell
carcinoma (SCC) are the most common types of NMSCs, with BCC representing approximately
75% of cases and SCC accounting for the remaining 25% (Alam et al., 2010). NMSC generally
has a low mortality rate, but older populations are showing an increased incidence rate which can
drastically affect quality of life (Guinot et al., 2018; Ouhib et al., 2015). Treatment options for
BCC and SCC are varied. Surgical excision is the most common treatment methodology, but
cryosurgery, topical chemotherapy, photodynamic therapy, and radiotherapy are all viable
treatment options (Alam et al., 2010; Likhacheva et al., 2017). However, not all patients are
candidates for surgical excision and radiotherapy procedures utilizing either external beam
radiation or brachytherapy have proven to be an effective alternative.
Radiation treatment options are also varied and include superficial x-rays, external
electron beams, electronic brachytherapy, and high dose rate (HDR) radionuclide brachytherapy.
Brachytherapy provides an effective means for treating NMSCs that are not able to be surgically
removed or conveniently treated with external beam radiotherapy. The word “brachy” is Greek
for “short distance” and deals with the placement of radioactive sources either directly onto or
into the treatment area. Modern brachytherapy practices can have the source applied inside a
body cavity (intracavitary), placed directly into a body tissue (interstitial), directed across a
tissue boundary into a bodily passage such as the esophagus or lung (transluminal), or placed on
the surface of the body (surface-mold/contact technique). The most commonly used isotope for
HDR brachytherapy is Iridium-192 (Ir-192). Ir-192 has a half-life of 74.2 days and emits γ rays
1

with a mean energy of 380 keV at a dose rate of approximately 7.5 Gy/min at 1.0 cm, allowing
for patient treatment times lasting several minutes (Oncology Medical Physics, 2020).
The scope of this project is the implementation of a Harrison Anderson Mick (H.A.M)
applicator for HDR brachytherapy skin cancer treatment at Dixie Regional Medical Center and
the acceptance and commissioning of the Varian Bravos HDR afterloader. Currently only
intracavitary brachytherapy is performed at this clinic, so this project would add the capability to
treat both SCCs and BCCs with surface brachytherapy. These types of malignancies are
generally treated with external beam electrons because of their shorter range of penetration
compared to photons, but there have been times when gantry angle and treatment location have
proven challenging. Using a flexible skin applicator would allow for alternative delivery options
not previously available. Commissioning of the H.A.M applicator was performed as well as
dosimetry verification using Gafchromic EBT3 film. Localization and reproducibility of the
applicator between fractions was determined, along with general prescription depths and doses.
Treatment planning techniques were also developed for ease of future implementation.
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2) MATERIALS AND METHODS
2.1) Varian Bravos HDR Afterloader
The Bravos is a new HDR afterloader developed by Varian. It contains a tungsten safe
that houses an Ir-192 source encased in stainless steel with a maximum installable activity of 15
Ci (555 GBq) (Varian, 2020). The source capsule is welded to a flexible wire made of stainlesssteel capable of extending to a length of 160 cm and traveling at a maximum speed of 100 cm/s
(Bellezzo et al., 2019). There are 30 possible treatment channels with a potential for 100 dwell
positions per channel and a wire positioning accuracy of ±1 mm.
The Bravos system also contains several new features that were not present in the
predecessor HDR afterloader, the GammaMedplus iX. The transit time algorithm of the source
has been reformulated in order to consider the movement of the source from the afterloader to
the most distal dwell position. There now exists an option for the differentiation between rigid
and flexible applicators which changes the force threshold used for source retraction (Bellezzo et
al., 2019). Channel length verification is now performed prior to treatment and the system will
automatically adjust for minor discrepancies. Channel length can be adjusted at the treatment
console prior to treatment while also retaining the same dwell time and positions relative to
channel length. It is now possible to add a distal position correction at a resolution of 1 mm prior
to treatment. The treatment system also requires the completion of a pretreatment checklist.
Patient identity and treatment setting verification are mandatory checklist fields, but additional
checklist items can be added manually. This checklist and the channel length verification must
be completed before the initiation of treatment. A comparison of the different features between
the Bravos and its predecessor the GammaMedplus iX is presented in Table 1.
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Feature

GammaMedplus iX

Bravos

CamScale device

Absent

Present

Transit
time
algorithm

calculation Accounts only for transit time Considers source movement
between dwell positions
from afterloader to most distal
dwell position

Source speed

63 cm/s

100 cm/s

Obstruction verification

Checked
treatment

Number of channels

24

30

Channel length

Fixed at 130 cm

50 – 160 cm

Channel length verification

Absent

Present

twice

before Checked
once
during
pretreatment and again prior
to treatment

Use of coded transfer guide Absent
tubes

Coded guide tubes can be used
in channels 1 – 3

Rigid and flexible applicator Push test performed only for All channels capable, but push
differentiation
channels 1 – 19
test is optional
Distal position correction

Possible to add offset but not Possible to correct an offset at
able to correct it during 1 mm resolution at console
pretreatment
prior to treatment

Distal position display at end 1 mm offset from source
of channel (ex. 130.0 cm)
position to the end of the
channel is displayed as if there
is no offset (ex. 130.0 cm)

1 mm offset from source
position to the end of the
channel is displayed (ex.
129.9 cm)

Pretreatment checklist

Treatment can only be
delivered after approving a
checklist with mandatory
fields for patient identity and
treatment setting. Additional
checklist items can also be
added by the user

No mandatory checklist

Table 1: GammaMedplus iX and Bravos HDR afterloader feature comparison. (Bellezzo et al.,
2019)
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Another new feature of the Bravos is the addition of the CamScale. The CamScale is
separate device from the Bravos afterloader and is primarily designed for daily QA and source
wire position verification. The CamScale and Bravos are presented in Figure 1.

Figure 1: The CamScale (left) and Bravos HDR afterloader (right). (Varian, 2020)
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Correct positioning of the CamScale is critical to proper position verification. The CamScale
needs to be placed at approximately 50 ± 1.5 cm and is connected to the afterloader using a
special guide tube inserted into Channel 1 (Bellezzo et al., 2019). Figure 2 shows the CamScale
properly attached to the Bravos afterloader. A laser is projected from the CamScale onto the
afterloader and needs to be aligned with a small box present on the front end of the afterloader.
Alignment with this box ensures that the CamScale is at the proper distance to accurately
position the dummy and source wire. A close-up view demonstrating appropriate laser
alignment is shown in Figure 3.

Figure 2: Bravos with attached CamScale. The special guide tube is designed to be inserted into
Channel 1 and the red laser projected onto the front of the Bravos ensure proper positioning at 50
± 1.5 cm.
6

Figure 3: Close up view of positioning laser. The laser is designed to be centered within the
confines of the small box on the front of the Bravos afterloader. This allows for an easy visual
reference to ensure that CamScale positioning is correct.

The inside of the CamScale consists of a calibrated metal ruler with 0.5 mm resolution
and three 1080p video cameras designed to capture the dummy and source wire at positions of
90, 120, and 150 cm (Bellezzo et al., 2019). The images taken at each of these dwell positions
are then analyzed by the system to locate the tips of both the dummy and source wires. If the
deviation from where the systems thinks the tips are and the visual position verification is greater
than 1 mm then it is suggested that a recalibration is performed where the user manually aligns
the system to the wire tips and the position is re-verified. An example of the printed report after
a position verification test is shown in Figure 4. The full Bravos commissioning report is
presented in Appendix A as a supplemental document.
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Figure 4: Position verification test report. Results for the dummy cable at each position is
presented on the left and the source cable is presented on the right. Arrows identify the tips of
each wire and the report lists the offsets at each dwell position.
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2.2) H.A.M Applicator
The Harrison Anderson Mick (H.A.M) applicator is a flexible flab of silicone rubber
designed to facilitate the placement of a radioactive source delivered from a remote afterloader
for the surface treatment of the skin, mucosa, or tumor bed (Eckert & Ziegler, 2019). The
applicator contains a set number of treatment catheters placed inside the flexible rubber pad. This
allows for direct connection to an HDR remote afterloader as well as consistent source-to-tissue
spacing of 5 mm. H.A.M. applicators containing both five and ten treatment catheters are shown
in Figure 5.

Figure 5: H.A.M. applicators. Applicators containing both five and ten treatment catheters are
shown above. The length and thickness of each applicator is the same, as well as the source-totissue distance and spacing between catheters. Only the width varies between the two and that
correlates with the number of possible channels.
9

Although the number of treatment catheters will determine the width, the applicators
have set dimensions of 22.5 cm length and 0.8 cm thickness. Each treatment catheter is spaced 1
cm apart from each other and the source-to-tissue distance is maintained at 0.5 cm on the
treatment side of the applicator. The treatment side of the applicator is clearly labeled, and 0.3
cm deep slits are made in the space between each treatment catheter to allow for additional
flexibility. It is advised that these applicators not be cut or modified in order to maintain their
material integrity as H.A.M. applicators are designed for single patient use (Eckert & Ziegler,
2019). Because of the asymmetry in the treatment catheter depth (0.5 cm on the treatment side
and 0.3 cm on the opposite side) it is imperative that the correct applicator side is applied to the
patient prior to treatment. A closer view of the H.A.M. applicator is presented in Figure 6.
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Figure 6: A closer view of the 5 cm H.A.M. applicator. Dimensions of the applicator are shown.
Also visible are the markings noting to “KEEP THIS SIDE AWAY FROM TISSUE” and a ruler
that allows for easy indexing of applicator positioning on the patient.

Upon initially receiving the applicators, each treatment catheter extends for
approximately 1 m from the end of the applicator. This allows for each treatment catheter to be
cut to the user desired length. For our purposes, all treatment catheters were cut to a length of 60
cm. The applicators are connected to the Bravos afterloader with the guide tubes normally used
for breast treatments. These guide tubes measure 100 cm and have a twist cap that allows for
tightening over the flexible treatment catheters. The 160 cm combined length of guide tube and
treatment catheters correlated to the maximum allowable length of the Bravos system.
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2.3) H.A.M. Applicator Commissioning
Quality assurance and commissioning of the H.A.M applicator was conducted in
accordance with the American Association of Physicists in Medicine (AAPM) Task Group (TG)
56 report guidelines that were applicable to these applicators (Howie et al., 2018; Nath et al.,
1997). Physical dimensions, and applicator integrity was analyzed for each of the two H.A.M.
applicators. Positional accuracy of the source within each treatment catheter was analyzed using
the PermaDoc phantom shown in Figure 7. The PermaDoc is a source positioning tool that
allows for irradiation of a piece of radiochromic film. It contains line markers spaced 1 cm apart
capable of being imprinted on the film at each source dwell position. Each applicator was
aligned with the PermaDoc system and a test plan was developed to deliver dwell positions 2 cm
apart in each treatment channel. Source positioning was then measured at each treatment
channel to ensure that the source had moved the correct distance.
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Figure 7: PermaDoc phantom source positioning tool. The upper most marker is 0.5 cm from the
next line, but each line after that is consistently spaced 1 cm apart. A strip of film is placed inside
the phantom and during HDR source exposure the positioning lines of the phantom are imprinted
on the film allowing for source position analysis.

Each applicator was placed on top of two slabs of solid water: a 5 cm thick base and 0.3 cm thick
slab chosen so that film dosimetry can be measured at a common prescription depth. CT images
using a GE Optima were conducted to verify the absence of occlusions within the treatment
catheters. These images were then imported into Eclipse treatment planning system (TPS) for
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the dual purpose of verifying that each treatment catheter was visible and clear of occlusions and
for treatment planning.

2.4) Dosimetric Verification
Verification of the dose distributions were performed using Gafchromic EBT 3 film.
This type of film has near tissue equivalency and is designed for the measurement of absorbed
doses of ionizing radiation in the range of 0.2 to 10 Gy (Ashland, 2020). It consists of an active
layer of material sandwiched between two layers of a matte-polyester substrate, as shown in
Figure 8. The active layer contains a marker dye, stabilizers, and other components that give the
film functional energy independence while also allowing for real time development after
exposure to ionizing radiation.

Figure 8: Structure of the Gafchromic EBT3 film. The active layer contains a marker dye and
other materials that give the film near energy-independent response and real time development
post-exposure. (Ashland, 2020)

After exposure the film was then scanned using an EPSON Expression 10000XL photo
scanner and RIT113 v.6.8.64 software was used for all film analysis. Scanner flatbed uniformity
14

was analyzed by scanning a 33.02 cm by 43.18 cm large blank sheet of EBT3 film and using the
RIT software analysis tools to determine the area with the most uniform response. A sheet of
black poster board was fitted over the scanner read area and a 15 cm x 15 cm square was cut out
over the area of most uniform response. The board minimizes additional light transmission
during the scan which may affect the film reading. This setup is presented in Figure 9.

Figure 9: EPSON Expression 10000XL film scan area. The 15 cm x 15 cm square cut out
represents the area of the flatbed scanner with the most uniform response. All film used for
dosimetry purposes was scanned within this area.
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Several sources (Ayoobian et al., 2016; Bassi et al., 2019; Palmer et al., 2013) used linear
accelerators for their film dose calibration prior to HDR measurements, so a 6 MV photon
fluence pattern with dose ranging from 0 to 950 cGy was created and delivered to film using a
TrueBeam linear accelerator. This dose calibration fluence pattern also served to create a flatbed
non-uniformity correction for our scanning surface using the RIT software. A random test
pattern was then irradiated with 6 MV photons to confirm the calibration.
A film handling and scanning protocol was implemented for each film containing dose.
Gloves were worn to prevent smudging on both the film and scanner glass. The large size sheets
of EBT3 film were cut into smaller sheets prior to irradiation. Dose calibration was conducted
on the film lot that was used for each dose analysis. The film scanning procedures and
parameters we used aligned well with other literature sources (Ferreira et al., 2009). At least four
test scans were performed in order to warm up the scanner bulb. Films were scanned using 48bit color and at a resolution of 72 dpi and saved as a Tagged Image File Format (.tif). Scans
were zoomed in on the film area. The complete EPSON scanner settings are shown in Figure 10,
the save settings are shown in Figure 11, and the zoom settings are shown in Figure 12.
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Figure 10: EPSON film scanner settings.

Figure 11: EPSON film file save settings.
17

Figure 12: EPSON film zoom settings. Each film was scanned within the 15 cm x 15 cm square
area cut out of the poster board.

2.5) Treatment Planning
Treatment planning using the applicator flap was conducted in Eclipse BrachyVision.
Dose prescription depth and fractionation schemes were taken from the Groupe Européen de
Curiethérapie and European Society for Radiotherapy & Oncology Advisory Committee in
Radiation Oncology Practice (GEC-ESTRO ACROP) and American Brachytherapy Society
(ABS) recommendations (Guinot et al., 2018; Ouhib et al., 2015). ABS recommend treatment
volumes for skin brachytherapy as a 5 mm lateral expansion of the gross tumor volume (GTV) to
create the clinical target volume (CTV), an additional 1.5 mm lateral expansion to the CTV to
create the planning target volume (PTV), and a margin of 1 mm for depth uncertainty. The
standard prescription depth when using surface applicators is 3 – 5 mm under the skin and 5 mm
18

source-to-tissue distance (Guinot et al., 2018; Iftimia, 2016; Ouhib et al., 2015). Recommended
dose prescription and fractionation schemes from various sources are presented in Table 2.

ABS (Ouhib et al., 2015)

40 Gy over 10 fractions
42 Gy over 6 fractions

GEC-ESTRO ACROP (Guinot et al., 2018)

51 – 54 Gy over 17 – 18 fractions
40 – 48 Gy over 10 – 12 fractions
50 – 60 Gy over 10 – 12 fractions
40 Gy over 8 fractions

Iftimia (2016)

51 Gy over 17 fractions

Table 2: Dose prescription and fractionation schedules from various sources.

The H.A.M. applicator is designed to produce an isodose distribution such as that shown
in Figure 13.
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Figure 13: H.A.M. Applicator isodose distribution. The consistent source-to-tissue distance of
0.5 cm and 1 cm spacing between treatment catheters is designed to lower dose to the skin and
allow for a more uniform dose distribution at distances of approximately 3 cm. (Eckert & Ziegler,
2020)

A 300 cGy and 500 cGy plan was created and normalized to a central reference line 0.3
cm below the surface of the flap. A sheet of film was sandwiched between the solid water
placing it at the point of normalization and the plans were generated. A coronal dose plane was
then exported from the TPS at this reference point for analysis with the film. The isodose plan
generated in Eclipse and the verification setup are shown in Figures 14 and 15, respectively.
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Figure 14: Isodose plan developed in Eclipse. This plan delivered 300 cGy and was normalized
to a central reference line 0.3 cm below the surface of the flap. A coronal dose plane was exported
from the plan for analysis with irradiated film.

Figure 15: Isodose verification experimental setup. A sheet of EBT film was placed between two
slabs of solid water (5 cm and 0.3 cm). The isodose plan was then run and the irradiated film was
scanned and compared to the equivalent dose plane exported from the TPS.
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Initial calibration of the EBT3 film was conducted using 6 MV photons delivered from a
TrueBeam linear accelerator and delivering a fluence pattern with a dose range of 0 – 950 cGy.
A random test pattern was irradiated and then compared with the isocenter dose plane exported
from Eclipse. This is shown in Figure 16. The excellent agreement between the two affirmed
that the dose calibration was sufficient for photons but still needed to be tested for HDR.

Figure 16: Test pattern for film dose verification. Vertical and horizontal dose profiles are shown
comparing the scanned film to the exported dose plane from the TPS. Excellent agreement is
shown between the two confirming the dose calibration was for external beam photons. This test
pattern had a dose range from 0 to 550 cGy.

Uniformity of the HDR isodose distribution under a bolus was measured by irradiating
film and comparing it to the appropriate dose plane. Both low (300 cGy) and high (500 cGy)
isodoses were analyzed with an applied median 5 x 5 filter. The results for the 300 cGy and 500
cGy HDR dose tests are shown in Figure 17 and 18, respectively. The dose plane for the HDR
22

was taken 0.8 cm from the source dwell positions, placing it at the spot of the film (0.5 cm
source-to-tissue distance + 0.3 solid water depth). As shown in Figures 17 and 18, there is very
good agreement between the planned and delivered doses at a depth of 0.3 cm, the nominal
treatment prescription depth. This verified that the dose calibration conducted using photons on
a linear accelerator was suitable for use of an HDR source.

Figure 17: 300 cGy isodose delivered from H.A.M. applicator. Vertical and horizontal dose
profiles are shown. Comparison between the planned and delivered dose is very good. The biggest
inconsistency is only seen in the spots near the film edges of the vertical profile.
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Figure 18: 500 cGy isodose delivered from H.A.M. applicator. Vertical and horizontal dose
profiles are shown. Very good agreement is shown between the planned and delivered dose.
Minor inconsistencies between the two can be attributed to variations in the film uniformity.

Validation of the treatment planning techniques were conducted in two stages: initial
dose verification under bolus material followed by end-to-end testing using a Stereotactic Endto-End Verification (STEEV) phantom. Initial planning dose verification used the 10 cm
applicator. A 0.3 cm thick flexible bolus was placed on top of a 5 cm slab of solid water. CT
marker wire was used to designate a PTV for planning purposes. The 10 cm H.A.M. applicator
flap was placed over the wire and a CT scan was taken. The flexible bolus material was chosen
to minimize the air gaps present when placing the applicator over the wire. A slab of solid water
0.3 cm thick was tested, but the air gaps present with the applicator placed over the wire was
unacceptable. This setup is presented in Figure 19.
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Figure 19: Initial TPS plan verification setup. The 10 cm H.A.M. applicator was used to treat a
designated PTV designated by the CT marker wire. General prescription treatment depth is 0.3
cm, so a 0.3 cm flexible skin bolus was used. After planning, EBT3 film was placed under the skin
bolus for analysis.

After the scans were imported to the TPS the following structures were contoured: Body,
Skin, Wire, PTV, Loading Volume, any additional OARs. The Body structure is automatically
contoured during import, but it may need editing in order to separate it from the applicator. The
Skin is a 2 – 3 mm inner wall extracted from the body. The Wire is necessary to outline the PTV
and must be manually contoured. After the wire is contoured, the PTV is defined by extracting a
3 mm inner wall from the skin under the area outlined by the marker wire. With the PTV
contoured, margins are added in order to define the Loading Volume. Dwell positions can then
be placed within this Loading Volume if desired. Finally, depending on the treatment location,
appropriate OARs can be contoured if needed.
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A dose of 300 cGy was prescribed to a depth of 3 mm. Applicators were added to each
of the 10 treatment channels and equal dwell times were initially added. A volume optimization
was then performed using the following DVH objectives for the PTV and Skin: PTV D90% >
100% Rx; PTV V100% > 95%; Skin D0.04cc < 145% Rx; Skin D1cc < 125% Rx. When the
volume optimization was completed, the dose was manually shaped in order to better conform to
the PTV and the plan was exported to the Bravos for treatment. A piece of EBT3 film was
placed underneath the 0.3 cm flexible skin bolus and the plan was generated. A coronal dose
plane at the location of the film was then exported from the TPS for comparison to the irradiated
film.
End-to-end testing using the STEEV phantom was performed after verifying planned
dose using the solid water and flexible bolus. This phantom was chosen to test how the
applicator operates during delivery over a curved surface. The STEEV phantom is a head and
neck phantom constructed of tissue-equivalent materials that simulates the internal anatomy of a
real patient. This phantom is presented in Figure 20.
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a)

b)
Figure 20: STEEV phantom. a) An external view of the phantom. b) The internal anatomy of the
phantom designed to simulate a real patient. (CIRS, 2013)
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A marker wire was placed on the scalp of the phantom to designate a PTV. A
thermoplastic mask was stretched over the phantom and a marker was used to outline the wire.
The 5 cm H.A.M. applicator was placed over the wire and a complete outline of the applicator
was drawn on the mask. The applicator was taped to the mask and a CT scan was taken. To
minimize the air gaps from the marker wire, the mask was cut around the wire outline and the
wire removed. The applicator was then taped back in to place and a second CT was taken. This
setup is presented in Figure 21.

Figure 21: End-to-end test setup on the STEEV phantom.
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In Eclipse, the two scans were fused. The wire was contoured on the scan that contained
it, and with the two scans registered together, that structure was then transferred to the scan
without the wire. The body, skin, PTV, and loading volume were all contoured on the scan
without the wire. Applicator placement required going through each slice to accurately locate
the treatment channel tips and place each of the five applicators. Dwell positions were placed
into the loading volume located over the PTV. A 300 cGy dose was prescribed to the PTV at a
depth of 0.3 cm. A volume optimization was performed using the same DVH metrics as before.
Because the location of the dwell positions was offset from the treatment channel tips, a copy of
the plan was created for qualitative dose and positioning analysis using EBT3 film. Four
reference points were added to the plan and a TG-43 second check was conducted using a
document acquired from Utah Valley Hospital. The applicator was repositioned on the phantom
and the plan was run to ensure that delivery was not hindered by the curved surface.
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3) RESULTS
3.1) H.A.M. Applicator Commissioning
Measured dimensions of both H.A.M. applicator flaps are presented in Table 3. Each
applicator fit the measurement criteria listed by the manufacturer with a slight difference seen in
the depth of the applicator. This measured difference was only applicable on the side that is not
facing the patient and the advertised 0.5 cm source-to-tissue distance was measured and verified
for each applicator.

SN# 16092

Length (cm)

Width (cm)

Depth (cm)

Manufacturer

22.5

5.0

0.8

Measured

22.5

5.0

0.9

Difference

0.0

0.0

0.1

SN# 16093

Length (cm)

Width (cm)

Depth (cm)

Manufacturer

22.5

10.0

0.8

Measured

22.5

10.0

0.9

Difference

0.0

0.0

0.1

Table 3: Measured dimensions of each H.A.M. applicator flap compared to manufacturer
specifications.

No signs of damage were visible on either of the H.A.M. applicators. There is a slight
crease in between each of the treatment channels on the side that is furthest away from the
patient’s skin. This allows for greater flexibility of the flap while still maintaining a solid barrier
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and consistent 0.5 cm source-to-tissue distance around curved surfaces. There were no air gaps
present between the slab and the skin. Each treatment channel was measured to be 1 cm apart.
Treatment channels measured 0.2 cm in diameter and extended 21.7 cm into the flap and
approximately 1 m outside of the flap.
The long length of the catheters allowed them to be cut to any desired length. Each
catheter was cut to 60 cm for consistency. When connected to a 100 cm guide tube the source
can travel the maximum length of 160 cm consistently from the afterloader. This distance was
verified for each treatment channel of both applicators using a length verification device and the
Bravos system push test.
Source positioning using the PermaDoc phantom was verified with Gafchromic EBT3
film and is shown in Figure 22. Planned dwell positions 2 cm apart were created for each
treatment channel. The tip of the treatment channel was aligned with the second line from the
top of the PermaDoc which accounts for the slight discrepancy in alignment. However,
consistency in source spacing is apparent and measured from the image.

31

Figure 22: 5 cm applicator source position verification. The PermaDoc phantom system was
utilized for these measurements. Consistency in the 2 cm planned dwell positions in each treatment
channel verified from the film. Slight offset from line markers caused by aligning applicator index
to second line from the top.

A CT scan of each applicator verified that all the treatment channels are visible and were
free from occlusion. This is presented in Figure 23.
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Figure 23: CT scan of the 5 cm applicator. Viewing planes were placed at the center of treatment
channels. The black lines are air and verifies that each channel is easily viewable and there is
nothing inside the channel that can block the wire.

3.2) Treatment Planning

3.2.1) Initial TPS Verification
Dwell positions of this plan were offset from the tip of the applicators and a qualitative
analysis of the exposed film verified their positioning. Qualitative comparison between the
planned dose distribution and delivered dose to film is presented in Figure 24. This shows that
the delivered plan fits within the expected size and shape of the PTV. Verification of the
treatment planning dose showed good agreement when compared to the TPS dose plane and is
presented in Figure 25. This initial analysis of dose distribution and film dose at depth verified
that the system could deliver a multi-channel plan to the H.A.M. applicator.

33

a)

b)
Figure 24: Qualitative comparison between the treatment planning and delivered dose. a) Planned
dose distribution generated to treat a PTV under a 0.3 cm flexible bolus. Initial dwell positions
were offset from the tip of the applicator. b) The same plan delivered to film. The film was placed
at the prescription depth of 0.3 cm under the bolus and compared to the coronal plane of the TPS.
Qualitative comparison between to two shows the expected size and shape of the PTV to be treated.
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Figure 25: Initial treatment planning dose verification. Film was placed under the 0.3 cm flexible
skin bolus and showed very good agreement with the planned dose from the TPS.

3.2.2) End-to-end Testing
A thermoplastic mask was successfully placed over the STEEV phantom to simulate
patient immobilization as shown in Figure 21. The H.A.M. applicator was positioned over the
PTV and a marker was used to outline the applicator for accurate repositioning. Two CT scans of
the STEEV phantom were taken: one with the marker wire present and another with the marker
wire removed. These scans were successfully fused and contoured. Planning was conducted on
the scan without the marker wire present. All dwell positions were placed into the Loading
Volume structure, which was designated as a 1.5 cm volume above the PTV. This meant that the
first dwell position for each treatment channel was placed a distance from the tip of each
channel. Volume optimization was performed using the following objectives for the PTV and
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Skin: PTV D90% > 100% Rx; PTV V100% > 95%; Skin D0.04cc < 145% Rx; Skin D1cc <
125% Rx. This plan is presented in Figure 26.

Figure 26: End-to-end STEEV test plan.

3.2.3) Quality Assurance
Pre-treatment quality assurance was conducted prior to treatment of the STEEV phantom.
Since the initial source dwell positions can often be located a distance away from the tip, a
qualitative assessment of dwell position and dose shape was performed. A copy of the treatment
plan was created, and the applicator was placed on a strip of EBT3 film. The tip of each
treatment channel was aligned with a dark line drawn on the film and the planned treatment
performed. The first dwell positions were then measured from this line and confirmed with the
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planning system. The measured film confirmed the dwell positions and overall shape of the
PTV. This is presented in Figure 27.

a)

b)
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c)
Figure 27: Qualitative verification of dwell positions and tumor shape. a) Contoured PTV to be
treated. The loading volume structure would encompass the PTV and is where the source dwells
will be placed. b) 3D view of the 100% isodose encompassing the PTV. Planned dwell positions
are noticeably offset from the applicator tips in order to provide the appropriate dose coverage. c)
Qualitative analysis using film verified the shape of the dose shown above. Since the first dwell
position of each treatment channel was offset from the applicator tip, this was also measured and
verified using EBT3 film.

An independent second check of the treatment plan was conducted using a document
acquired from Utah Valley hospital. This document uses the 1D point source TG-43 formalism
for dose calculation along with four reference points at different locations on the treatment plan.
Monte-Carlo dosimetry of the source calculated by Ballester et al. (2001) was used to determine
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the dose rate constant and radial dose function. The cartesian coordinates of each source dwell
position is used to calculate the point dose to the designated reference points. The dose to the
reference points from each dwell position was summed and compared to the point dose from the
treatment planning system. Calculated dose difference between the treatment planning system
and the independent second check was shown to be under 5%. This second check verified that
the created plan was capable of being delivered correctly.
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4) DISCUSSION
This project effectively demonstrated the commissioning of H.A.M. applicators for
surface brachytherapy in the treatment of nonmelanoma skin cancer. Each applicator measured
within the manufacturer’s specifications and was free from damage. There was a consistent 0.5
cm source-to-tissue spacing for each applicator. All treatment catheters for both applicators were
cut to 160 cm and verified with both the length verification device and the Bravos system push
test. All treatment catheters were free from occlusion and visualized well from a CT scan. Using
the breast guide tube, each treatment catheter could easily connect to the Bravos afterloader and
deliver an accurate treatment. Source positioning was consistent in spacing and delivery, and
planned dose was shown to be accurately delivered even with the applicator placed on a curved
surface. Criteria established by the AAPM TG-56 report for quality assurance of applicators
used for HDR brachytherapy required the “evaluation and measurement of dimensions/serial
numbers; dosimetric evaluation of applicators; and applicator radiographs to determine correct
source position and mechanical integrity” (Nath et al., 1997). Based on those criteria these
applicators are suitable to use for an HDR brachytherapy treatment.
Treatment planning using the applicators was an interesting process. Contouring was
straightforward and the recommended structures used for planning worked very well (Iftimia,
2016). Creating a Loading Volume structure using margins over the PTV was a novel idea and
allowed for a simple method of placing dwell positions within the PTV treatment region. What
ended up being the biggest challenge during the treatment planning process was determining the
position of each treatment channel within the applicator. When the flap was pressed flat against
a piece of film or solid water there is no issue at all, as evidenced in Figure 20. However,
locating each individual channel becomes increasingly challenging over a curved surface. When
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the H.A.M. flap was placed over the STEEV phantom it was positioned in a way to maximize
coverage of the PTV while avoiding placing the flap over the patient’s eyes. This placed the flap
at such an angle that none of the available viewing planes were able to easily detect the channel
positioning. The tips of each channel had to be located first in the sagittal viewing plane, and
then moving all viewing planes to that tip. Once that happened, each slice was analyzed in all
planes to determine channel location. This process was then repeated for each of the five
treatment channels. All channels were accurately located, but special care is going to have to be
taken when planning with larger applicator flaps over highly curved surfaces. The addition of
marker wires placed in every other treatment channel may help with applicator placement
Dose prescriptions for this project followed recommendations established by the ABS,
GEC-ESTRO ACROP, and Iftimia (2016) as presented in Table 2. These resources took
aggregated data to make their recommendations and was the primary source for the prescription
planning in this work. The recommendations made generally prescribed dose to a depth of 0.3 –
0.5 cm under the skin surface. These prescriptions were usually not deeper than 0.5 cm because
that would result in considerably higher skin surface doses. Fractional doses ranged from 3 – 7
Gy per fraction over a schedule of 6 – 18 fractions. The goal of these doses and fractionation
schemes is to achieve a BED target of 65 – 70 Gy (Ouhib et al., 2015). All film measurements
of this project were prescribed to a depth of 0.3 cm. From the literature this appeared to be the
most common prescription depth, so it was important to verify the dosimetric accuracy at that
distance under the skin. The prescription dose during testing was chosen to be on the lower end
of the generally prescribed doses at 300 cGy. Isodose testing of the applicator showed that
higher doses could still be used and present very good agreement at the prescription depth, so the
actual fractional dose prescribed for treatment would be the decision of the radiation oncologist.
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Volume optimization utilizing TG-43 formalism for calculating dose was used for this
project. Investigations into the limitations of TG-43 dose calculation formalism by Boman et al.
(2017) make note that increasing scatter conditions with the addition of bolus placed on top of
the applicator would help to improve dose agreement at a prescription depth of 1 cm. However,
placement of an additional 1 – 2 cm of bolus on top of the applicator could lead to possible
discomfort of the patient for particularly large lesions on the scalp. Furthermore, 1 cm is also
much deeper than is generally prescribed for treatment. In contrast, Granero et al. (2014) notes
that when using an Ir-192 source at a typical prescription depth of 0.5 cm, no bolus is necessary
as at those clinical prescription depths the dose differences is not clinically relevant. The
recommendation of not including a bolus during treatment was also made by Ouhib et al. (2015).
One of the questions that arose during the planning optimization process was the use of
AcurosBV or TG-43 for dose calculation. Both calculation methods used the following criteria:
PTV D90% > 100%; goal PTV V100% > 95%; skin D0.04cc < 145% Rx; goal skin D1.0cc <
125% Rx (Iftimia, 2016). This criterion was input during the dose optimization process and
worked consistently well for the plans tested. Differences between the optimized plans using
AcurosBV were minimal compared to those using TG-43. The benefits of using TG-43 for
planning purposes were the real-time dose shaping and the point dose dwell time modification.
Using TG-43 formalism for dose calculation also simplified the dose point independent second
check process. With slight modifications to the Utah Valley QA document, dose discrepancies
between the calculated dose and TPS were well below 5%.
Positional accuracy and reproducibility between fractions will be one of the primary
challenges during treatment. Set-up photos are going to be extremely important for use as a
reference. Communication between staff regarding the appropriate set-up is also going to be
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paramount. Drawing the associated PTV on the patient’s skin and making sure that the marking
remains between fractions will help with reproducibility. The benefits to using the H.A.M.
applicator flaps regarding repositioning include the fact that they are translucent and contain an
indexing ruler already printed on the side facing away from the patient. This should allow for
ease of repositioning of the applicator prior to placement if proper set-up notes are taken during
simulation.
For this project a thermoplastic mask was used for patient immobilization. A marker wire
was placed directly on the patient’s skin delineating the PTV and the mask was stretched over it.
The applicator was positioned and outlined with a marker prior to being taped to the mask and a
scan was taken. To prevent potential air gaps caused by the wire on the skin, the area around the
PTV was cut out of the mask, the applicator was reapplied on the skin, and another scan was
taken. This type of process will likely not be used on an actual patient in order to limit the
number of CT scans the patient receives, but the concept of multiple simulations will be
necessary. Iftimia (2016) recommended two simulations: the first simulation places the
immobilization device on the patient and delineates the PTV, then the second simulation scans
the patient with the applicator flap attached to the immobilization device used. This process
allows for ensuring that options for applicator placement are taken into consideration prior to
simulation and treatment.
While this project was focused on the application of H.A.M. flaps for surface
brachytherapy, the next step in establishing a surface brachytherapy program will be the use of
Valencia style applicators. These are conical applicators made of tungsten alloy that place the
source 1 – 1.5 cm above the surface of the skin. Circular or oval apertures attached to the
applicator allow for treatment of surface lesions of various sizes. A set of these surface
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applicators was recently acquired, and work has already started in the characterization of dose
and output factors at clinically relevant depths (surface to 0.5 cm). Furthermore, 3D printing of
custom surface molds is also being considered. These would enable patient specific molds to be
created and used with the H.A.M. applicator for treatment.
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5) CONCLUSION
The H.A.M. applicator was commissioned and tested for use during HDR brachytherapy
in the treatment of skin cancer. Both applicators were free from any damage and each measured
accurately to manufacturers specifications. Dosimetry of each applicator was verified using
Gafchromic EBT3 film and RIT113 film analysis software. End-to-end testing was able to
accurately transfer and deliver a treatment plan. An independent second check of the dose and
dwell position location away from the tip verified that the plan would be delivered accurately.
Prescription dose and treatment depth recommendations are made, but that will ultimately be an
oncologist decision. Patient immobilization techniques were discussed and will be primarily
dependent on the individual patient and treatment location.
The Varian Bravos HDR afterloader was also accepted and commissioned during the
course of this project. It contains several upgrades to usability compared to its predecessor the
GammaMedplus iX and the capability of housing a 15 Ci source allows for faster patient
treatment times. The push test verification prior to treatment accurately accounts for any offsets
to ensure that source position is accurately placed. Being able to adjust the length of the
treatment channel from the computer console while maintaining source dwell timing and position
is also a benefit of the Bravos system. The addition of the CamScale is a novel inclusion as well.
This device allows for position verification and calibration of the source prior to treatment and is
simple to set up and use.
Future implementation of Valencia style applicators for surface brachytherapy use is
currently underway. Comparison of TG-43 and AcurosBV dose calculation algorithms at
clinically relevant depths has currently been completed. Output factor measurements using a
diamond detector at clinical depths as well as determination of applicator placement and
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reproducibility is planned. With the use of both the H.A.M flap and Valencia applicators, a
comprehensive HDR surface brachytherapy program can be instituted at Dixie Regional Medical
Center.
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APPENDIX A: Bravos Commissioning Report
Varian Bravos HDR Afterloader (SN# 651026) Commissioning Report
The Bravos by Varian is an HDR remote afterloader capable of housing and delivering an
Ir-192 source with a maximum source strength of 15 Ci. It contains 30 treatment channels and a
maximum source travel distance of 160 cm. Varian Bravos commissioning consisted of
measuring source hot spot, source output, verifying source dwell positioning, independently
verifying system dwell timing, interlock testing, and CamScale position verification calibration.
The CamScale is a source positioning device that is developed by Varian to operate in
conjunction with the Bravos system. Interlocks were tested and verified through the Bravos
computer console and with a survey meter.

Measurements:
Source Hot Spot and Output
Source hot spot and output was measured using the Standard Imaging HDR 1000 Plus
ionization well chamber and a Standard Imaging CDX-2000B electrometer. A treatment channel
length of 132 cm was programmed into the Bravos system. Hot spot was determined by having
10 dwell positions with a step size of 0.5 cm going from 129 cm to 124.5 cm. A 10 second dwell
time was used. Hot spot was determined to reside at 127.5 cm.
Source output was measured by using a 20 second dwell time at the determined hot spot
position of 127.5 cm.
Data is saved on Q: HDR > Dixie > QA
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CamScale Position Calibration
The CamScale is a source position verification and calibration tool unique to the Bravos
system. A laser projected from the CamScale onto the Bravos allows for accurate positioning
and a designated guide tube is used to connect the two systems. 3 cameras inside the system
show dummy and source cable position at 150.0 cm, 120.0 cm, and 90.0 cm. Cable tip and offset
from these positions can be measured and calibrated.
A position verification test (PVT) is automatically built into the Bravos computer system.
The test was conducted, and the cable tips were calibrated. Another PVT was performed after
calibration for confirmation.
Data is saved on Q: HDR > Dixie > QA

Source Positioning
Source positioning was performed using a Mick Radio-Nuclear Instruments PermaDoc
Phantom. A new catheter tube capable of connecting to the Bravos guide tubes was installed into
the phantom. A strip of Gafchromic EBT3 film was placed inside the phantom and underneath
the treatment catheter. 10 dwell positions spaced 1 cm apart were programmed with a 2 second
dwell time. Source position was analyzed on the film and imprinted marker lines.
System position accuracy with a programmed offset was also analyzed. The Bravos has a
new feature where a push test will determine the channel tip and automatically correct for
positional discrepancy. A 0.2 cm and 0.5 cm offset to the catheter tip was programmed into the
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PermaDoc test. In both cases the Bravos automatically corrected to the appropriate treatment
length.
Data is saved on Q: HDR > Dixie > QA

System Dwell Timing and Interlock Test
System dwell timing was verified independently with a stopwatch. A single 60 second
dwell time was programmed. Timer was started when the source reached its dwell position and
stopped when source began retraction.
The 60 second dwell time also allowed for interlock testing. Each interlock was triggered
with the source in position and verified automatic source retraction. Opening the door; turning
the system key to off position; interrupting treatment manually from computer console; and
pressing Emergency Off button were tested and source retraction verified inside treatment room
with survey meter.
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Figure 28: Source Hot Spot and Output
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Figure 29: CamScale Position Verification and Calibration
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Figure 30: Source Position Verification
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APPENDIX B: H.A.M. Applicator Commissioning Report
H.A.M. Applicator Commissioning Report
The Harrison Anderson Mick (H.A.M.) applicator is a silicone rubber flab designed for
the use of HDR surface brachytherapy. Treatment catheters are embedded into the applicator
and can be cut to a user desired length. Commissioning of H.A.M. applicator flaps consisted of
measuring the dimensions of the applicator and comparing them to manufacturer specifications;
visual inspection of applicator integrity; source positional accuracy within each treatment
channel; and CT scanning verification of treatment channel visibility. Dosimetric assessment
was also performed for each applicator using Gafchromic EBT3 film and compared to associated
dose planes exported from Eclipse treatment planning system (TPS).

Measurements:
Applicator Dimensions and Integrity Analysis
The applicator was physically measured using a meter length ruler. Width, length, and
thickness of the applicator was measured and compared to the manufacturer specifications.
Specified 0.5 cm source-to-tissue distance from the center of each treatment catheter was
verified. All treatment catheters were cut to 160 cm and this length was verified using a cable
wire length verification device.
Each applicator was visually inspected for signs of damage. No signs of damage were
found but it needs to be noted that on each applicator there is a slight crease in between each
treatment channel that allows for additional flexibility. This is inherent to applicator design and
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does not affect applicator integrity. Designation of which side is to face away from the patient’s
skin is clearly marked on each applicator.

Source Position Accuracy
Source position accuracy was measured using a Mick Radio-Nuclear Instruments
PermaDoc phantom. A strip of Gafchromic EBT3 film was placed underneath the applicator.
The tip of the applicator was aligned with the first long line of the phantom. A test plan was
programmed to deliver dwell positions every 2 cm with a 4 second dwell time in each channel of
the applicator. Source alignment and dwell positioning in each treatment channel was verified
after by scanning the film using an EPSON Expression 10000XL photo scanner and measuring
in Eclipse Brachytherapy 2D Entry
Data is saved on Q: HDR > Surface

CT Image Verification
The applicator was placed on top of a slab of solid water and a CT scan was taken. Each
scan was imported into Eclipse treatment planning system (TPS). Visualization of the applicator
and each treatment channel verified that they were all free from occlusion.
Data is saved on Q: HDR > Surface
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Dosimetric Evaluation
Accurate delivery of dose using the applicator was verified using Gafchromic EBT3 film.
A 300 cGy and 500 cGy plan was created in Eclipse that utilized all treatment channels. The plan
was normalized to a central reference line 0.8 cm from the source. The EBT3 film was placed
under a slab of 0.3 cm thick solid water and the film was irradiated. The film was scanned and
compared to the TPS exported dose plane using RIT113 film analysis software.
Another plan was created simulating possible treatment. A marker wire was placed on a
0.3 cm flexible skin bolus to outline a potential PTV. The applicator was placed over this
marker wire and scanned. A 300 cGy plan prescribed to a 0.3 cm depth was created. A piece of
EBT3 film was placed under the bolus and the irradiated film was scanned and compared to the
TPS exported dose plane.
Data is saved on Q: HDR > Surface

Conclusion
Using applicable TG-56 guidelines for applicator quality assurance, the H.A.M.
applicator is suitable for use during HDR procedures.
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SN# 16092

Length (cm)

Width (cm)

Depth (cm)

Manufacturer

22.5

5

0.8

Measured

22.5

5

0.9

Difference

0

0

0.1

SN# 16093

Length (cm)

Width (cm)

Depth (cm)

Manufacturer

22.5

10

0.8

Measured

22.5

10

0.9

Difference

0

0

0.1

Table 4: Applicator Dimensions
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Figure 31: Source Position Accuracy
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a)

b)
Figure 32: CT Image Verification. a) 5 cm applicator. b) 10 cm applicator.
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a)

b)

c)

Figure 33: Dosimetry Verification. a) 300 cGy. b) 500 cGy. c) 300 cGy planned PTV
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